Get started
Author

Wancai Xing

Observed name: WANCAI XING
ORCID: 0000-0003-3647-6943
Observed ORCID: 0000-0003-3647-6943
OpenAlex ID: A5088522393
Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway
2015 · Youjun Li, Hao Zhou, et al. · Cell Research · 146
PDF
GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models
2022 · Man Zhang, Yining Zhang, et al. · European Journal of Pharmacology · 12
The conformation change and tumor suppressor role of Merlin are both independent of Serine 518 phosphorylation
2017 · Wancai Xing, Meng Li, et al. · Biochemical and Biophysical Research Communications · 7
Tetramerization of SATB1 is essential for regulating of gene expression
2017 · Minying Zheng, Wancai Xing, et al. · Molecular and Cellular Biochemistry · 7
823-P: Molecular and Pharmacological Properties of GZR4, a Once-Weekly Insulin Analog
2024 · WANCAI XING, WEI CHEN, et al. · Diabetes · 4
1822-P: Pharmacokinetic and Pharmacodynamic Profiles of GZR102 Injection, a Novel Once-Weekly Fixed-Ratio Combination of Insulin GZR4 and GLP-1 Analog Bofanglutide
2026 · YAN HUANG, ANSHUN HE, et al. · Diabetes
Corrigendum to “GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models” [Europ. J. Pharmacol. 928 (2022) 175107]
2026 · Man Zhang, Yining Zhang, et al. · European Journal of Pharmacology
GZR101, a Novel Premixed Insulin for the Treatment of Diabetes Mellitus
2025 · Wei Chen, Cheng Cui, et al. · Naunyn-Schmiedeberg s Archives of Pharmacology
819-P: A Novel Premix Insulin GZR101 for Diabetes Management
2024 · WEI CHEN, WANCAI XING, et al. · Diabetes
Works count: 9
Citation count: 176
H-index: 4
I10-index: 2
Year
Topic
Type